EL7.AI
StocksMedium•19 November 2026•
1 min read

GE HealthCare MRI Contrast Agent Meets Primary Endpoint in Phase 2 Study

Key Facts

1GE HealthCare announced that its manganese-based contrast agent mangaciclanol met its primary endpoint in a Phase 2 study.
2The results support the advancement of the agent into Phase 3 of the LUMINA clinical trial.

GE HealthCare announced that its manganese-based contrast agent mangaciclanol met its primary endpoint in a Phase 2 study. Benzinga reported that these results support the advancement of the agent into Phase 3 of the LUMINA clinical trial.

GEHC closed at $83.66 on November 18, 2026, having reached a day high of $83.99 and a low of $81.13 during that session. The successful clinical progression reduces R&D risk for the company's new product line within the medical imaging sector.

Open on chart